August 2017
A new anti-MUC1-antibody with high affinity and selectivity for modified MUC1 glycopeptides was developed at La Rioja University.
New protein based nanoparticles were obtained at University of Cambridge by using microfluidic spray drying devices. These monodisperse protein nanoparticles are susceptible to surface modification and can be used for drug delivery purposes.
|
September 2016
From 6-9 of September the Members of the Protein Conjugates got together in Lisbon for the first ITN event, an exciting workshop entitled "An Introduction to Modern Bioconjugation" focused on the most recent advances on Protein Modification.
|
February 2017
A new method for the site-selective cysteine modification has been developed at FFUL, based on the site-selective installation of 3HQ-maleimide.
|
News
December 2015
Three methods of disulfide re-bridging have been developed by UCL
|
News
November 2015
Check for PhD opportunities within the ProteinConjugates ITN network!
|
|
October 2017
On the 17th of October 2017 the Mid-term Meeting took place at UKRO in Brussels, Belgium. Through a 10min oral presentation, the students introduced themselves, presented their projects and first results to the European Commission representative from the Research Executive Agency (REA) and to an external expert. All the supervisors from the beneficiary Institutions were present to discuss the ITN progress and next steps.
|
July 2017
On the 25-26th July 2017 took place the ProteinConjugate 1st Symposium & 2nd Workshop at the Wellcome Collection London. This meeting focused on the ESR individual research projects and the acquisition of complementary training aspects like presentation, science communication and Leadership & Management competences.
|
2017
Next ITN Workshop will be in London 2017
|
April 2017
A new method for the site-selective modification of disulfide bridges in proteins for the installation of salicylhydroxamate (SHA) via a 2-steps reaction has been developed at MPI-P
A new method for site-selective modification of antibodies using cysteine residues resulting from disulfide cleavage was developed at IMM
|
News
November 2015
Grant Agreement has been signed by all partners.
|
|
